# Repligen (RGEN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RGEN
## Company Profile
- Ticker: RGEN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Life Science Tools
## Stock Data
- Close: 175.42 USD
- Market cap: 6832669546.2 USD
- Last updated: 2026-10-13
## Business Overview
### Bioprocessing Technology Supplier
Repligen is a global life sciences company focused on technologies and systems used in biologic drug manufacturing. Its customers include biopharmaceutical developers and contract development and manufacturing organizations seeking greater efficiency, control, and scalability in production.
### Four Core Technology Areas
The company’s portfolio spans Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Together, these technologies address critical steps from upstream through downstream biologic manufacturing.
### Consumables and Workflow Integration
Many Repligen products are recurring-use consumables embedded in validated manufacturing processes. This creates durable customer relationships and demand linked to biologic production volumes, process intensification, and capacity expansion.
### Biopharma and CDMO Customer Base
Repligen sells to biologic drug developers, commercial manufacturers, and contract development and manufacturing organizations. Its products can be adopted during process development and remain in use as a therapy advances toward larger-scale and commercial production.
### Cell Therapy Supply Chain Expansion
Repligen’s planned acquisition of BioLife Solutions is intended to broaden its consumables and systems presence across cell therapy workflows. The transaction represents an expansion of the company’s manufacturing platform and supply-chain capabilities rather than a single-asset development event.
## Why The Stock Is Moving

As of Oct 13, 2026, RGEN closed up 1.69% at $175.42. No new same-company headline was identified in the current news window.

## Future Catalysts

- Repligen’s watchpoints are bioprocess order recovery, new consumable adoption, and any sign that capital spending is loosening. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- 2026-10-06 13:05 EST — [Repligen Completes Acquisition of BioLife Solutions](https://biopharmsignal.com/news/RGEN/repligen-completes-acquisition-of-biolife-solutions-0e73cde6) — Source: Repligen
- 2026-08-26 11:30 EST — [Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference](https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-wells-fargo-21st-annual-healthcare-conference-c33c028f) — Source: Repligen
- 2026-07-28 11:00 EST — [Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance](https://biopharmsignal.com/news/RGEN/repligen-reports-second-quarter-2026-financial-results-and-updates-full-year-202-465808e8) — Source: Repligen
- 2026-07-22 10:00 EST — [Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media](https://biopharmsignal.com/news/RGEN/repligen-to-acquire-biolife-solutions-expanding-its-cell-therapy-capabilities-wi-b25607c1) — Source: Repligen
- 2026-07-15 11:30 EST — [Repligen to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RGEN/repligen-to-report-second-quarter-2026-financial-results-f6af0b9d) — Source: Repligen